Targeting angiotensin II type I receptors to reduce the risk of stroke in patients with hypertension.
The incidence of stroke is rising among the elderly population. Hypertension is the single most important contributor to stroke, and hypertension treatment and control is the most important intervention to prevent it. Blood pressure reduction by any means will substantially reduce the risk of stroke. However, accumulating evidence indicates that angiotensin receptor blocker-based regimens may provide additional benefits in the prevention of stroke. This effect seems to be particularly prominent in high-risk patients and patients with isolated systolic hypertension. The pathophysiological mechanisms have not been clearly delineated, but favourable remodelling of the left atrium and reduction of the risk of atrial fibrillation has been suggested. In addition, blockade of the central AT1 receptors and stimulation of AT2 receptors and/or preferential reduction of central pressure by angiotensin receptor blockers may account for the beneficial protective effect.
Veterans Affairs and Georgetown University, VAMC 151-E, 50 Irving Stir NW, Washington DC 20422, USA.
Dimitris P
DP
Papadopoulos
Vasilios
V
Papademetriou
D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage*; D000818:Animals; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism*; D044140:Receptor, Angiotensin, Type 1 / Q000378:metabolism; D012307:Risk Factors; D020521:Stroke / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism*
D047228:Angiotensin II Type 1 Receptor Blockers; D044140:Receptor, Angiotensin, Type 1